Featured Story

Cancer Dx startup Helomics joins U.K. genomics initiative alongside big biopharmas

Helomics is lending its tumor profiling technology and diagnostic expertise to a U.K. genomics initiative, teaming up with Big Pharma and researchers to uncover new biomarkers and develop advanced tests.

Cleveland Clinic study finds ST2 biomarker can predict heart failure

At the American College of Cardiology annual meeting, researchers from the Cleveland Clinic and Duke University Medical Center determined that the level of the ST2 protein is a good predictor of adverse events and death in heart failure patients.

Dako strikes another cancer companion Dx deal with Amgen

Dako is extending its collaboration with pharma giant Amgen to develop companion diagnostic products for drug development and research. Neither side is revealing financial details, but Dako, now an Agilent company, said the deal will focus on personalized medicine and tests that pair patients with suitable treatments.

GE Healthcare's pathology arm to use Omnyx's software for digital analysis of specimens

GE Healthcare announced that its diagnostic laboratory company, Clarient, will soon deploy Omnyx's proprietary software, as pathology pivots away from visual diagnosis and toward quantitative computer-based tools.

Roche joins forces with Sigma-Aldrich to distribute biochemical reagents

Roche inked an exclusive global deal with Sigma-Aldrich to market and distribute its biochemical reagents portfolio. Under the terms of the deal, Sigma-Aldrich will present and distribute Roche's kits and enzymes for cellular analysis, proteomics and conventional PCR applications.


From Our Sister Sites


A new survey finds an astonishing "fat pet gap" in the U.S. According to the study, 58% of cats and 53% of dogs were overweight last year. Yet more than 90% of these pets' owners incorrectly identified their four-legged friends as normal weight.


The Obama Administration rolled out its 5-year plan to combat antibiotic-resistant bacteria on Thursday, and it was met with widespread disdain from critics who say it doesn't do enough to prevent livestock producers from using the drugs in ways that endanger both animal and human health.